HER2阳性乳腺癌治疗的研究进展  

Research Progress in the Treatment of HER2-positive Breast Cancer

作　　者：范雪娇 吴涛[1] 袁冶 FAN Xuejiao;WU Tao;YUAN Ye(Department of Breast Surgery One,Affiliated Tumor Hospital of Xinjiang Medical University,Urumqi 830000,China)

机构地区：[1]新疆医科大学附属肿瘤医院乳外一科,新疆乌鲁木齐830000 [2]新疆医科大学护理学院,新疆乌鲁木齐830016

出　　处：《中国医学创新》2025年第11期184-188,共5页Medical Innovation of China

摘　　要：人表皮生长因子受体2(HER2)阳性乳腺癌是一种高度侵袭性的肿瘤亚型,其治疗策略一直是肿瘤研究领域的热点,在过去几十年中经历了显著的变革。随着对HER2阳性乳腺癌的深入理解,针对HER2阳性乳腺癌的治疗方法不断创新,显著改善了患者的生存预后。本文综述了HER2阳性乳腺癌治疗领域的最新研究进展,包括靶向药物、免疫治疗、细胞治疗及新型药物的研发情况。HER2-positive breast cancer is a highly aggressive tumor subtype,and its treatment strategies have been a hot topic in the field of cancer research and have undergone significant changes in the past few decades.With the in-depth understanding of HER2-positive breast cancer,treatments for HER2-positive breast cancer are continuously innovating,significantly improving the survival prognosis of patients.This article reviews the latest research progress in the field of HER2-positive breast cancer treatment,including the development of targeted drugs,immunotherapy,cell therapy,and new drugs.

关 键 词：HER2 阳性乳腺癌 靶向治疗 免疫治疗 治疗策略 

分 类 号：R737.9[医药卫生—肿瘤]